TrialJournal of Korean medical science2018

Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP).

Junshik Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.